Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
- CE marked test for patients with pancreatic ductal adenocarcinoma
- Prediction of response to first-line gemcitabine-based chemotherapy
- Developed and validated with real world data and samples
A tough cancer without prior assessment of potential treatment efficacy
Pancreatic cancer is an aggressive cancer. According to the
Pancreatic cancer is particularly insidious because it is a "silent" disease that causes no symptoms in its early stages. Often diagnosed at a late stage, this cancer has a poor prognosis. Few treatments are available: surgery and/or chemotherapy. For patients with locally advanced or metastatic cancer at the time of diagnosis, chemotherapy remains the only treatment option, whether it is based on gemcitabine or 5-FU, alone or in combination.
GemciTest®, an in-vitro diagnostic developed by Acobiom, is a predictive PCR test for response to gemcitabine-based chemotherapy in first-line treatment. This CE-marked molecular diagnostic identifies patients with pancreatic ductal adenocarcinoma (PDAC, a form of pancreatic cancer) whose transcriptomic profile is not favorable for the prescription of a first-line gemcitabine-based therapy (alone or in combination). This test will thus make it possible to guide patients towards another more suitable or more effective therapy, to avoid unnecessary side effects or toxicities, and thus to risk a "loss of chance" for these patients.
A new test based on the latest technologies
GemciTest has been developed with Acobiom's technology platform, which combines genomic and transcriptomic techniques (NGS sequencing, real-time PCR) with bioinformatics, biostatistics and artificial intelligence (machine learning) tools and programs for data processing and analysis.
Developed and validated using real-world data and samples, this molecular diagnostics is based on a proprietary combination of RNA markers present in blood. The test was evaluated in a confirmatory study to measure its sensitivity in predicting the response of PDAC patients to a gemcitabine-based chemotherapy in first-line treatment.
This confirmatory study demonstrated the value of using GemciTest® in clinics and also reveals the potential of RNA marker combinations in blood in the development of precision medicine and personalized therapy for patients with pancreatic cancer.
“The signature of this commercial agreement with
AboutGemciTest®
GemciTest® is a predictive molecular diagnostic for response to gemcitabine-based chemotherapy in first-line treatment. This CE-marked PCR test is intended for patients with pancreatic ductal adenocarcinoma (PDAC). This in-vitro diagnostic has been developed from Acobiom's technology platform, which combines genomic and transcriptomic techniques (NGS sequencing, real-time PCR) on the one hand, and bioinformatics, biostatistics and machine learning tools and programs for data processing and analysis on the other.
Developed and validated using real world data and samples, GemciTest® is based on a patented combination of RNA markers present in blood and has been evaluated in a confirmatory study. The clinical validation of this PCR test was performed on 336 patients (mean age 68.7; 37-88). Patients with a clinical benefit (OS > 8.7 months; PFS ≥3.5 months) identified by GemciTest® (29.7%) had significantly a longer PFS (5.3 vs. 2.8 months) and a longer OS (10.4 vs. 4.8 months). GemciTest® -positive patients had significantly longer PFS (HR=0.53 (95% CI: 0.31-0.92); p=0.023) and OS (HR=0.49 (95% CI: 0.29-0.85); p=0.0091).
About
For more information, please visit the website: www.eurobio-scientific.com
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech Indices, label Euronext European Rising Tech
Mnémonics: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP
About Acobiom
Acobiom is a biotechnology company specializing in the discovery of biological markers (biomarkers) and the development of innovative molecular diagnostics for applications in personalized medicine or precision medicine. Precision medicine aims at personalizing treatments according to certain biomarkers in order to obtain a better therapeutic effectiveness, to limit the side effects of a treatment and to ensure a better quality of life for the patient. The diagnostics developed by ACOBIOM respond to these needs and support medical teams in choosing the most effective treatment best suited to the transcriptomic profile of each patient. These diagnostics are developed from biomarkers, identified by the company's scientific team, which has more than 20 years of expertise in the study of gene expression and a technological platform combining genomics, transcriptomics, bioinformatics, biostatistics (data science) and machine learning (artificial intelligence). Founded in 1999, Acobiom is located in the Euromedicine Biopole in Montpellier (
For more information:www.acobiom.com
Media and investor Contacts
Eurobio Scientific Calyptus
Jean-
Denis Fortier, Managing director Tel.: +33 1 53 65 68 68 - eurobio-scientific@calyptus.net
Tel.: +33 1 69 79 64 80
Acobiom
Philippe Outrebon
investor@acobiom.com
Attachment
- Eurobio-Scientific_Acobiom_gemcitest_EN
© OMX, source